Hemostemix (CVE:HEM) Shares Up 30% – Should You Buy?

Hemostemix Inc. (CVE:HEM) traded up 30% during mid-day trading on Wednesday . The stock traded as high as C$0.15 and last traded at C$0.13. 430,289 shares traded hands during mid-day trading, a decline of 10% from the average session volume of 480,285 shares. The stock had previously closed at C$0.10.

Hemostemix Trading Up 30.0%

The firm’s 50-day moving average is C$0.10 and its 200-day moving average is C$0.14. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The firm has a market cap of C$18.94 million, a price-to-earnings ratio of -3.79 and a beta of 0.20.

Insider Activity at Hemostemix

In other Hemostemix news, Director Peter Alan Lacey purchased 200,000 shares of Hemostemix stock in a transaction that occurred on Thursday, March 6th. The stock was acquired at an average price of C$0.15 per share, with a total value of C$30,000.00. 10.43% of the stock is currently owned by insiders.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.